Ann: Paradigm Receives Ethics Approval for Ross River Trial, page-5

P3 still required....longer trial, more numbers, more certainty of data re effectiveness and side effects....but risk of failure quite low once through P2 as I understand re biotechs....hayfever area is a whole area I didn't know about re use of PPS but it is an area where I will be closely looking at re cases at work....valuations will start to be applied re possible licensing deals once through P2 as the company is then holding a product which will more than likely get through a P3 trial and the product has enormous market potential, both in the allergy area....Paul alluded that more coming in this area...and the arthritis market re osteoarthritis....the current value of the company will look very low once thru current P2 trials....IND application may be made so the P3 trial can be conducted in the US as well as here??, this may be a question to put to Paul....FastTrack may be available post P2 for RRV arthralgia trial which would lead to even quicker market access/licensing deals,

kind regards, SEAH.